HIV-1 Vaccine Development After STEP

被引：84

作者：

Barouch, Dan H. ^{[1
,2
]}

Korber, Bette ^{[3
,4
]}

机构：

[1] Beth Israel Deaconess Med Ctr, Div Vaccine Res, Boston, MA 02115 USA

[2] Ragon Inst MGH MIT & Harvard, Boston, MA USA

[3] Los Alamos Natl Lab, Los Alamos, NM USA

[4] Santa Fe Inst, Santa Fe, NM 87545 USA

来源：

ANNUAL REVIEW OF MEDICINE | 2010年 / 61卷

基金：

美国国家卫生研究院;

关键词：

HIV-1; viral diversity; antigen design; T cell vaccines; antibody vaccines; HUMAN-IMMUNODEFICIENCY-VIRUS; T-CELL RESPONSES; IMMUNE-RESPONSES; NEUTRALIZING ANTIBODIES; SUBTYPE-B; IMMUNOGENICITY EVALUATION; ENVELOPE GLYCOPROTEIN; VIRAL REPLICATION; LYMPHOCYTE ESCAPE; PHASE-1; SAFETY;

D O I：

10.1146/annurev.med.042508.093728

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Despite more than 2 5 years of concerted worldwide research, the development of a safe and effective HIV-1 vaccine remains elusive. Prototype antibody-based and T cell-based HIV-1 vaccines have failed to show efficacy in clinical trials to date. Next-generation HIV-1 vaccine candidates are in various stages of preclinical and clinical development, but key scientific obstacles pose major challenges for the field. Critical hurdles include the enormous global diversity of the virus and the challenges associated with generating broadly reactive neutralizing antibody and cellular immune responses. We review the current state of the HIV-1 vaccine field and outline strategies that are being explored to overcome these roadblocks.

引用

页码：153 / 167

页数：15

共 99 条

[11] Escape and compensation from early HLA-B57-Mediated cytotoxic T-lymphocyte pressure on human immunodeficiency virus type 1 Gag alter capsid interactions with cyclophilin A [J].

Brockman, Mark A. ;

Schneidewind, Arne ;

Lahaie, Matthew ;

Schmidt, Aaron ;

Miura, Toshiyuki ;

DeSouza, Ivna ;

Ryvkin, Faina ;

Derdeyn, Cynthia A. ;

Allen, Susan ;

Hunter, Eric ;

Mulenga, Joseph ;

Goepfert, Paul A. ;

Walker, Bruce D. ;

Allen, Todd M. .

JOURNAL OF VIROLOGY, 2007, 81 (22) :12608-12618

[12]

BUCHBINDER S, 2009, KEYST S HIV VACC KEY

[13] Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial [J].

Buchbinder, Susan P. ;

Mehrotra, Devon V. ;

Duerr, Ann ;

Fitzgerald, Daniel W. ;

Mogg, Robin ;

Li, David ;

Gilbert, Peter B. ;

Lama, Javier R. ;

Marmor, Michael ;

del Rio, Carlos ;

McElrath, M. Juliana ;

Casimiro, Danilo R. ;

Gottesdiener, Keith M. ;

Chodakewitz, Jeffrey A. ;

Corey, Lawrence ;

Robertson, Michael N. .

LANCET, 2008, 372 (9653) :1881-1893

[14] Leveraging Hierarchical Population Structure in Discrete Association Studies [J].

Carlson, Jonathan ;

Kadie, Carl ;

Mallal, Simon ;

Heckerman, David .

PLOS ONE, 2007, 2 (07)

[15] Phylogenetic Dependency Networks: Inferring Patterns of CTL Escape and Codon Covariation in HIV-1 Gag [J].

Carlson, Jonathan M. ;

Brumme, Zabrina L. ;

Rousseau, Christine M. ;

Brumme, Chanson J. ;

Matthews, Philippa ;

Kadie, Carl ;

Mullins, James I. ;

Walker, Bruce D. ;

Harrigan, P. Richard ;

Goulder, Philip J. R. ;

Heckerman, David .

PLOS COMPUTATIONAL BIOLOGY, 2008, 4 (11)

[16] Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with DNA and recombinant adenoviral vaccine vectors expressing Gag [J].

Casimiro, DR ;

Wang, FB ;

Schleif, WA ;

Liang, XP ;

Zhang, ZQ ;

Tobery, TW ;

Davies, ME ;

McDermott, AB ;

O'Connor, DH ;

Fridman, A ;

Bagchi, A ;

Tussey, LG ;

Bett, AJ ;

Finnefrock, AC ;

Fu, TM ;

Tang, AM ;

Wilson, KA ;

Chen, MC ;

Perry, HC ;

Heidecker, GJ ;

Freed, DC ;

Carella, A ;

Punt, KS ;

Sykes, KJ ;

Huang, LY ;

Ausensi, VI ;

Bachinsky, M ;

Sadasivan-Nair, U ;

Watkins, DI ;

Emini, EA ;

Shiver, JW .

JOURNAL OF VIROLOGY, 2005, 79 (24) :15547-15555

[17] Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene [J].

Casimiro, DR ;

Chen, L ;

Fu, TM ;

Evans, RK ;

Caulfield, MJ ;

Davies, ME ;

Tang, A ;

Chen, MC ;

Huang, LY ;

Harris, V ;

Freed, DC ;

Wilson, KA ;

Dubey, S ;

Zhu, DM ;

Nawrocki, D ;

Mach, H ;

Troutman, R ;

Isopi, L ;

Williams, D ;

Hurni, W ;

Xu, Z ;

Smith, JG ;

Wang, S ;

Liu, X ;

Guan, LM ;

Long, R ;

Trigona, W ;

Heidecker, GJ ;

Perry, HC ;

Persaud, N ;

Toner, TJ ;

Su, Q ;

Liang, XP ;

Youil, R ;

Chastain, M ;

Bell, AJ ;

Volkin, DB ;

Emini, EA ;

Shiver, JW .

JOURNAL OF VIROLOGY, 2003, 77 (11) :6305-6313

[18] Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector [J].

Catanzaro, Andrew T. ;

Koup, Richard A. ;

Roederer, Mario ;

Bailer, Robert T. ;

Enama, Mary E. ;

Moodie, Zoe ;

Gu, Lin ;

Martin, Julie E. ;

Novik, Laura ;

Chakrabarti, Bimal K. ;

Butman, Bryan T. ;

Gall, Jason G. D. ;

King, C. Richter ;

Andrews, Charla A. ;

Sheets, Rebecca ;

Gomez, Phillip L. ;

Mascola, John R. ;

Nabel, Gary J. ;

Graham, Barney S. .

JOURNAL OF INFECTIOUS DISEASES, 2006, 194 (12) :1638-1649

[19] Structure of an unliganded simian immunodeficiency virus gp120 core [J].

Chen, B ;

Vogan, EM ;

Gong, HY ;

Skehel, JJ ;

Wiley, DC ;

Harrison, SC .

NATURE, 2005, 433 (7028) :834-841

[20] Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines [J].

Connor, RI ;

Korber, BTM ;

Graham, BS ;

Hahn, BH ;

Ho, DD ;

Walker, BD ;

Neumann, AU ;

Vermund, SH ;

Mestecky, J ;

Jackson, S ;

Fenamore, E ;

Cao, Y ;

Gao, F ;

Kalams, S ;

Kunstman, KJ ;

McDonald, D ;

McWilliams, N ;

Trkola, A ;

Moore, JP ;

Wolinsky, SM .

JOURNAL OF VIROLOGY, 1998, 72 (02) :1552-1576

← 1 2 3 4 5 6 7 8 9 10 →